Animal models of Alzheimer's disease and frontotemporal dementia

Nature Reviews Neuroscience

Volumn 9, Issue 7, 2008, Pages 532-544

  Götz, Jürgen ^a   Ittner, Lars M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BETA SECRETASE; EPIGALLOCATECHIN GALLATE; GAMMA SECRETASE; GINKGO BILOBA EXTRACT; LACTOYLGLUTATHIONE LYASE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PACLITAXEL; PRESENILIN 1; PRESENILIN 2; QS 21; TACROLIMUS; TAU PROTEIN; VALOSIN CONTAINING PROTEIN;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; DISEASE MODEL; DROSOPHILA MELANOGASTER; DRUG TARGETING; EXPERIMENTAL MODEL; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL GENOMICS; GENE MUTATION; HUMAN; LEARNING; LONG TERM POTENTIATION; MASS SPECTROMETRY; MEMORY; MENINGOENCEPHALITIS; NERVE FIBER TRANSPORT; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; RNA INTERFERENCE; TRANSCRIPTOMICS; VACCINATION;

ANIMALIA; INVERTEBRATA; MUS; MUS MUSCULUS;

EID: 45749151056     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn2420     Document Type: Review

References (169)

1. Ballatore, C., Lee, V. M. & Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Rev. Neurosci. 8, 663-672 (2007).
2. Cummings, J. L. & Askin-Edgar, S. Evidence for psychotropic effects of acetylcholinesterase inhibitors. CNS Drugs 13, 385-395 (2000).
3. Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R. & Van Hoesen, G. W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1, 103-116 (1991).
4. Neary, D. et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria [see comments]. Neurology 51, 1546-1554 (1998).
5. Snowden, J. S. et al. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J. Neurol. Neurosurg. Psychiatry 70, 323-332 (2001).
6. Weder, N. D., Aziz, R., Wilkins, K. & Tampi, R. R. Frontotemporal dementias: a review. Ann. Gen. Psychiatry 6, 15 (2007).
7. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science 298, 789-791 (2002).
8. Lee, V. M., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159 (2001).
9. Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706 (1991).
10. Murrell, J., Farlow, M., Ghetti, B. & Benson, M. D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254, 97-99 (1991).
11. Mullan, M. et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nature Genet. 1, 345-347 (1992).
12. Nilsberth, C. et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nature Neurosci. 4, 887-893 (2001).
13. Bertram, L. & Tanzi, R. E. The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 115, 1449-1457 (2005).
14. Hutton, M. et al. Association of missense and 5β-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705 (1998).
15. Poorkaj, P. et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815-825 (1998).
16. Spillantini, M. G. et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. USA 95, 7737-7741 (1998).
17. Cruts, M. & Van Broeckhoven, C. Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet. (2008).
18. Baker, M. et al. Mutations in progranulin cause taunegative frontotemporal dementia linked to chromosome 17. Nature 442, 916-919 (2006).
19. Cruts, M. et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920-924 (2006). This study, together with reference 18, identifies null mutations in progranulin as a cause of taunegative frontotemporal dementia.
20. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133 (2006). This study shows that the tau-negative, ubiquitinpositive lesions in some forms of frontotemporal dementia and amyotrophic lateral sclerosis contain the protein TDP-43.
21. Gitcho, M. A. et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 63, 535-538 (2008).
22. Kabashi, E. et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genet. 40, 572-574 (2008).
23. Yokoseki, A. et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann. Neurol. 63, 538-542 (2008).
24. Ye, Y. et al. Inaugural Article: Recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum membrane. Proc. Natl Acad. Sci. USA 102, 14132-14138 (2005).
25. Neumann, M. et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J. Neuropathol. Exp. Neurol. 66, 152-157 (2007).
26. Kayasuga, Y. et al. Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behav. Brain Res. 185, 110-118 (2007).
27. Götz, J. et al. A decade of tau transgenic animal models and beyond Brain Pathol. 17, 91-103 (2007).
28. Götz, J. et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. Embo J. 14, 1304-1313 (1995).
29. Lewis, J. et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nature Genet. 25, 402-405 (2000). This study presented the first mouse model with NFT formation by expression of FTDP-17 (P301L) mutant tau.
30. Götz, J., Chen, F., van Dorpe, J. & Nitsch, R. M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ 42 fibrils. Science 293, 1491-1495 (2001).
31. Götz, J. et al. Transgenic animal models of Alzheimer's disease and related disorders: Histopathology, behavior and therapy. Mol. Psychiatry 9, 664-683 (2004).
32. Santacruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (2005). This study shows that NFT formation is not related to functional impairment in mice.
33. Higuchi, M. et al. Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies. J. Neurosci. 25, 9434-9443 (2005).
34. Forman, M. S. et al. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J. Neurosci. 25, 3539-3550 (2005).
35. Allen, B. et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340-9351 (2002).
36. Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351 (2007).
37. Bellucci, A. et al. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J. Pathol. 165, 1643-1652 (2004).
38. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nature Med. 12, 1005-1015 (2006).
39. Götz, J. Tau and transgenic animal models. Brain Res. Brain Res. Rev. 35, 266-286 (2001).
40. Roberson, E. D. et al. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754 (2007). This study shows that tau reduction protects from Aβ-mediated toxicity and excitotoxicity.
41. Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science 293, 1487-1491 (2001).
42. Bolmont, T. et al. Induction of tau pathology by intracerebral infusion of amyloid-β-containing brain extract and by amyloid-β deposition in APP x Tau transgenic mice. Am. J. Pathol. 171, 2012-2020 (2007).
43. Terwel, D. et al. Amyloid activates GSK-3β to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol. 172, 786-798 (2008).
44. Phiel, C. J., Wilson, C. A., Lee, V. M. & Klein, P. S. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435-439 (2003).
45. Liou, Y. C. et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 424, 556-561 (2003).
46. Pastorino, L. et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production. Nature 440, 528-534 (2006).
47. Oddo, S. et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles. Intracellular aβ and synaptic dysfunction. Neuron 39, 409-421 (2003). This study combines transgenic expression of mutant APP, PSEN1 and tau, achieving both Aβ plaque and NFT formation.
48. Casas, C. et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165, 1289-1300 (2004).
49. Holcomb, L. et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med. 4, 97-100 (1998).
50. Schmitz, C. et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 164, 1495-1502 (2004).
51. Wang, R., Wang, B., He, W. & Zheng, H. Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. J. Biol. Chem. 281, 15330-15336 (2006).
52. Ohno, M. et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41, 27-33 (2004).
53. McConlogue, L. et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 282, 26326-26334 (2007).
54. Willem, M. et al. β-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. Am. J. Pathol. 165, 1621-1631 (2004).
55. Ma, H. et al. Involvement of β-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activitydependent synaptic plasticity. Proc. Natl Acad. Sci. USA 104, 8167-8172 (2007).
56. Postina, R. et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 113, 1456-1464 (2004).
57. Bales, K. R. et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nature Genet. 17, 263-264 (1997).
58. Dodart, J. C. et al. Gene delivery of human apolipoprotein E alters brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 102, 1211-1216 (2005).
59. Wahrle, S. E. et al. Deletion of Abca1 increases Aβ deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280, 43236-43242 (2005).
60. Koldamova, R., Staufenbiel, M. & Lefterov, I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280, 43224-43235 (2005).
61. Hirsch-Reinshagen, V. et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 280, 43243-43256 (2005).
62. Wahrle, S. E. et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118, 671-682 (2008).
63. Hirokawa, N. & Takemura, R. Molecular motors and mechanisms of directional transport in neurons. Nature Rev. Neurosci. 6, 201-214 (2005).
64. Ishihara, T. et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751-762 (1999).
65. Stokin, G. B. et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307, 1282-1288 (2005). This study identifies correlates of impaired axonal transport in APP transgenic mice and AD brains. Formation of spheroids increases with reduced kinesin function.
66. Dixit, R., Ross, J. L., Goldman, Y. E. & Holzbaur, E. L. Differential regulation of dynein and kinesin motor proteins by tau. Science 319, 1086-1089 (2008).
67. Kamal, A., Stokin, G. B., Yang, Z., Xia, C. H. & Goldstein, L. S. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28, 449-459 (2000).
68. Kamal, A., Almenar-Queralt, A., LeBlanc, J. F., Roberts, E. A. & Goldstein, L. S. Kinesin-mediated axonal transport of a membrane compartment containing β-secretase and presenilin-1 requires APP. Nature 414, 643-648 (2001).
69. Goedert, M. & Spillantini, M. G. A century of Alzheimer's disease. Science 314, 777-781 (2006).
70. Magnani, E. et al. Interaction of tau protein with the dynactin complex. Embo J. 26, 4546-4554 (2007).
71. Driscoll, M. & Gerstbrein, B. Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nature Rev. Genet. 4, 181-194 (2003).
72. Wittmann, C. W. et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711-714 (2001). This study shows in D. melanogaster that tau-mediated neurodegeneration can occur in the absence of NFT formation.
73. Jackson, G. R. et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34, 509-519 (2002).
74. Dias-Santagata, D., Fulga, T. A., Duttaroy, A. & Feany, M. B. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J. Clin. Invest. 117, 236-245 (2007).
75. Arendt, T. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Prog. Neurobiol. 71, 83-248 (2003).
76. Khurana, V. et al. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr. Biol. 16, 230-241 (2006).
77. Ferrari, A., Hoerndli, F., Baechi, T., Nitsch, R. M. & Götz, J. β-amyloid induces PHF-like tau filaments in tissue culture. J. Biol. Chem. 278, 40162-40168 (2003).
78. Steinhilb, M. L., Dias-Santagata, D., Fulga, T. A., Felch, D. L. & Feany, M. B. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol. Biol. Cell 18, 5060-5068 (2007).
79. Fulga, T. A. et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nature Cell Biol. 9, 139-148 (2007). This study links tau pathology to the formation of actin-containing rods.
80. Takasugi, N. et al. The role of presenilin cofactors in the γ-secretase complex. Nature 422, 438-441 (2003).
81. Fossgreen, A. et al. Transgenic Drosophila expressing human amyloid precursor protein show γ-secretase activity and a blistered-wing phenotype. Proc. Natl Acad. Sci. USA 95, 13703-13708 (1998).
82. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
83. O'Nuallain, B. & Wetzel, R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl Acad. Sci. USA 99, 1485-1490 (2002).
84. Habicht, G. et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc. Natl Acad. Sci. USA 104, 19232-19237 (2007).
85. Bertram, L. et al. Family-based association between Alzheimer's disease and variants in UBQLN1. N. Engl. J. Med. 352, 884-894 (2005).
86. Li, A. et al. Isolation and characterization of the Drosophila ubiquilin ortholog dUbqln: in vivo interaction with early-onset Alzheimer disease genes. Hum. Mol. Genet. 16, 2626-2639 (2007).
87. Iijima, K. et al. Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: a potential model for Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 6623-6628 (2004).
88. Luheshi, L. M. et al. Systematic in vivo analysis of the intrinsic determinants of amyloid β pathogenicity. PLoS Biol. 5, e290 (2007).
89. Seidner, G. A., Ye, Y., Faraday, M. M., Alvord, W. G. & Fortini, M. E. Modeling clinically heterogeneous presenilin mutations with transgenic Drosophila. Curr. Biol. 16, 1026-1033 (2006).
90. Muqit, M. M. & Feany, M. B. Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nature Rev. Neurosci. 3, 237-243 (2002).
91. Micchelli, C. A. et al. γ-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. Faseb J. 17, 79-81 (2003).
92. Kraemer, B. C. et al. From the Cover: Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc. Natl Acad. Sci. USA 100, 9980-9985 (2003).
93. Miyasaka, T. et al. Progressive neurodegeneration in C. elegans model of tauopathy. Neurobiol. Dis. 20, 372-383 (2005).
94. Dickey, C. A. et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J. Neurosci. 26, 6985-6996 (2006).
95. Kraemer, B. C. & Schellenberg, G. D. SUT-1 enables tau-induced neurotoxicity in C. elegans. Hum. Mol. Genet. 16, 1959-1971 (2007).
96. Francis, R. et al. aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation. Dev. Cell 3, 85-97 (2002).
97. Schafer, W. F. Genetics of egg-laying in worms. Annu. Rev. Genet. 40, 487-509 (2006).
98. Smialowska, A. & Baumeister, R. Presenilin function in Caenorhabditis elegans. Neurodegener. Dis. 3, 227-232 (2006).
99. Ellerbrock, B. R., Coscarelli, E. M., Gurney, M. E. & Geary, T. G. Screening for presenilin inhibitors using the free-living nematode, Caenorhabditis elegans. J. Biomol. Screen 9, 147-152 (2004).
100. David, D., Hoerndli, F. & Götz, J. Functional Genomics meets neurodegenerative disorders Part I: Transcriptomic and proteomic technology. Prog. Neurobiol. 76, 153-168 (2005).
101. Hoerndli, F., David, D. & Götz, J. Functional genomics meets neurodegenerative disorders. Part II: Application and data integration. Prog. Neurobiol. 76, 169-188 (2005).
102. Ray, S. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Med. 13, 1359-1362 (2007).
103. Zhao, X. et al. Transcriptional profiling reveals strict boundaries between hippocampal subregions. J. Comp. Neurol. 441, 187-196 (2001).
104. Sandberg, R. et al. Regional and strain-specific gene expression mapping in the adult mouse brain. Proc. Natl Acad. Sci. USA 97, 11038-11043 (2000). This study shows differentially regulated genes in subregions of the hippocampus.
105. Zirlinger, M., Kreiman, G. & Anderson, D. J. Amygdala-enriched genes identified by microarray technology are restricted to specific amygdaloid subnuclei. Proc. Natl Acad. Sci. USA 98, 5270-5275 (2001).
106. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nature Rev. Mol. Cell Biol. 8, 101-112 (2007).
107. Ebneth, A. et al. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol. 143, 777-794 (1998).
108. David, D. C. et al. Proteomic and functional analysis reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 280, 23802-23814 (2005).
109. Melov, S. et al. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE 2, e536 (2007).
110. Lustbader, J. W. et al. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452 (2004).
111. Gillardon, F. et al. Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Proteomics 7, 605-616 (2007).
112. Colangelo, V. et al. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J. Neurosci. Res. 70, 462-473 (2002).
113. Ho, L. et al. Gene expression profiling of the tau mutant (P301L) transgenic mouse brain. Neurosci. Lett. 310, 1-4 (2001).
114. Götz, J., Chen, F., Barmettler, R. & Nitsch, R. M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276, 529-534 (2001).
115. Chen, F. et al. Role for glyoxalase I in Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 7687-7692 (2004).
116. David, D. C. et al. β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 6, 6566-6577 (2006).
117. Karsten, S. L. et al. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron 51, 549-560 (2006).
118. Dickey, C. A. et al. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J. Neurosci. 23, 5219-5226 (2003).
119. Lazarov, O. et al. Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice. Cell 120, 701-713 (2005). This study shows how environmental enrichment can reduce Aβ levels and improve memory deficits.
120. Selwood, S. P. et al. Gene expression profile of the PDAPP mouse model for Alzheimer's disease with and without Apolipoprotein E. Neurobiol. Aging Sep 29 2007 (doi:10.1016/j.neurobiolaging.2007.08.006).
121. Skovronsky, D. M. et al. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 7609-7614 (2000).
122. Klunk, W. E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306-319 (2004). This study shows that the Pittsburgh Compound-B (PIB) is a suitable PET tracer in vivo.
123. Bacskai, B. J. et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice. Proc. Natl Acad. Sci. USA 100, 12462-12467 (2003). This study introduces the Pittsburgh Compound-B (PIB) that binds to Aβ plaques in vivo.
124. Klunk, W. E. et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598-10606 (2005).
125. Maeda, J. et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 27, 10957-10968 (2007).
126. Higuchi, M. et al. 19F and 1H MRI detection of amyloid β plaques in vivo. Nature Neurosci. 8, 527-533 (2005).
127. Marjanska, M. et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl Acad. Sci. USA 102, 11906-11910 (2005).
128. Van Dam, D. & De Deyn, P. P. Drug discovery in dementia: the role of rodent models. Nature Rev. Drug Discov. 5, 956-970 (2006).
129. Lichtlen, P. & Mohajeri, M. H. Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem. 104, 859-874 (2008).
130. Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
131. Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916-919 (2000).
132. Oddo, S. et al. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281, 39413-39423 (2006).
133. Orgogozo, J. M. et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46-54 (2003).
134. Hock, C. et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554 (2003).
135. Asuni, A. A., Boutajangout, A., Quartermain, D. & Sigurdsson, E. M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115-9129 (2007).
136. Kulic, L. et al. Active immunization trial in Aβ(42)-injected P301L tau transgenic mice. Neurobiol. Dis. 22, 50-56 (2005).
137. Zhang, B. et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl Acad. Sci. USA 102, 227-231 (2005).
138. Dineley, K. T., Hogan, D., Zhang, W. R. & Taglialatela, G. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol. Learn. Mem. 88, 217-224 (2007).
139. -/- mice that tau is needed for Aβ-mediated toxicity.
140. Patel, N. V. et al. Caloric restriction attenuates Aβ-deposition in Alzheimer transgenic models. Neurobiol. Aging 26, 995-1000 (2005).
141. Halagappa, V. K. et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 26, 212-220 (2007).
142. Kim, D. et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. Embo J. 26, 3169-3179 (2007).
143. Rezai-Zadeh, K. et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25, 8807-8814 (2005).
144. Lim, G. P. et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25, 3032-3040 (2005).
145. Jayasooriya, A. P. et al. Perinatal omega-3 polyunsaturated fatty acid supply modifies brain zinc homeostasis during adulthood. Proc. Natl Acad. Sci. USA 102, 7133-7138 (2005).
146. Wang, J. et al. Moderate consumption of Cabernet Sauvignon attenuates Aβ neuropathology in a mouse model of Alzheimer's disease. Faseb J. 20, 2313-2320 (2006).
147. Youm, J. W. et al. Transgenic potato expressing Aβ reduce Aβ burden in Alzheimer's disease mouse model. FEBS Lett. 579, 6737-6744 (2005).
148. Cheng, H. et al. Mechanisms of disease: new therapeutic strategies for Alzheimer's disease - targeting APP processing in lipid rafts. Nature Clin. Pract Neurol. 3, 374-382 (2007).
149. Barnham, K. J., Masters, C. L. & Bush, A. I. Neurodegenerative diseases and oxidative stress. Nature Rev. Drug Discov. 3, 205-214 (2004).
150. Caccamo, A. et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49, 671-682 (2006).
151. Di Rosa, G., Odrijin, T., Nixon, R. A. & Arancio, O. Calpain inhibitors: a treatment for Alzheimer's disease. J. Mol. Neurosci. 19, 135-141 (2002).
152. Kukar, T. et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production. Nature Med. 11, 545-550 (2005).
153. Caccamo, A., Oddo, S., Tran, L. X. & LaFerla, F. M. Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 170, 1669-1675 (2007).
154. Rockenstein, E. et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 27, 1981-1991 (2007).
155. Glenner, G. G. & Wong, C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890 (1984).
156. Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 4245-4249 (1985).
157. McGowan, E. et al. Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47, 191-199 (2005).
158. Yan, Y. & Wang, C. Aβ40 protects non-toxic Aβ42 monomer from aggregation. J. Mol. Biol. 369, 909-916 (2007).
159. Vassar, R. et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741 (1999).
160. Edbauer, D. et al. Reconstitution of γ-secretase activity. Nature Cell Biol. 5, 486-488 (2003).
161. Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E. & Klug, A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl Acad. Sci. USA 85, 4051-4055 (1988).
162. Myers, A. J. et al. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum. Mol. Genet. 14, 2399-2404 (2005).
163. Meyer-Luehmann, M. et al. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 1781-1784 (2006). This study shows shared properties between prions and Aβ with regards to host and agent dictating pathology.
164. Lesne, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357 (2006).
165. Cleary, J. P. et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nature Neurosci. 8, 79-84 (2005).
166. Cheng, I. H. et al. Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282, 23818-23828 (2007).
167. Willem, M. et al. Control of peripheral nerve myelination by the β-secretase BACE1. Science 314, 664-666 (2006). This study identifies a role for the β-secretase BACE in processing neuregulin.
168. McIntosh, A. M. et al. The effects of a neuregulin 1 variant on white matter density and integrity. Mol. Psychiatry 9 Oct 2007 (doi: 10.1038/sj.mp.4002103).
169. Schubert, C. Alzheimer disease: BACE1 branches out. Nature Med. 12, 1123 (2006).